Acinetobacter News and Research

RSS

Xellia to develop new antibiotics effective against multi-drug resistant Gram-negative bacteria

Xellia Pharmaceuticals, a fully integrated specialty pharmaceutical company focusing on the global anti-infective market, announced today that it is developing new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria.

26 Feb 2013

FDA designates two of Cubist’s Phase 3 antibiotic candidates

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated two of the company's Phase 3 antibiotic candidates, CXA-201 (ceftolozane/tazobactam) and CB-315, as Qualified Infectious Disease Products (QIDP).

6 Dec 2012

Current hospital cleaning protocol may be inadequate to rid MDR A. baumannii

Current hospital cleaning protocol may be inadequate to rid patient rooms of multidrug-resistant (MDR) Acinetobacter baumannii, according to a study in the December issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).

1 Dec 2012

WellStar Health System implements Xenex’s room disinfection system

WellStar Health System was the first to implement and is the only health system in metro-Atlanta using Xenex Healthcare Services' room disinfection system in its patient and operating rooms. A "green," mercury-free technology, the Xenex system is the fastest, safest and most effective method for the advanced cleaning of hospital rooms, scientifically proven to destroy all major classes of microorganisms that cause hospital acquired infections (HAIs), such as MRSA and Clostridium difficile (C. diff).

29 Nov 2012

Metalloacid surfaces may be answer to hospital-acquired infections

Coating surfaces in metalloacids may help control the spread of hospital-acquired infections, suggest study findings.

14 Nov 2012

Xenex offers room disinfection devices to hospitals hit by Hurricane Sandy

Xenex Healthcare Services, the world leader in UV room disinfection systems, today announced it is making its room disinfection devices available to hospitals affected by Hurricane Sandy.

3 Nov 2012

Xenex Healthcare Services receives GSA contract to purchase room disinfection systems

Xenex Healthcare Services, the world leader in UV room disinfection systems, today announced it has been awarded a U.S. General Services Administration (GSA) contract, making it even easier for federal agencies (including Veterans Affairs hospital systems) to purchase Xenex's room disinfection systems.

11 Oct 2012

LpxC-1 can effectively treat antibiotic-resistant infections

A new type of antibiotic can effectively treat an antibiotic-resistant infection by disarming instead of killing the bacteria that cause it. Researchers report their findings in the October 2 issue of mBio-, the online open-access journal of the American Society for Microbiology.

3 Oct 2012

Xenex's pulsed xenon UV more effective than bleach in decontaminating C. diff surfaces

Healthcare associated infections (also referred to as HAIs or hospital acquired infections) are the fourth leading cause of death in the United States, costing more than $30 billion each year. Evidence continues to mount that hospital cleanliness plays a role in the spread of HAIs, which are caused by deadly pathogens such as C. diff, MRSA, VRE and Acinetobacter.

19 Sep 2012

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

13 Sep 2012

Kalidex announces presentation of data on KPI-10 against MDR strains at ICAAC

Kalidex Pharmaceuticals, a privately-held anti-infective company, today announced the presentation of data on its lead development candidate KPI-10, a broad spectrum, next-generation fluoroquinolone, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, September 9 through 12.

7 Sep 2012

Study identifies certain small molecule chemicals that can disrupt quorum sensing in A. baumanni

Acinetobacter baumanni, a pathogenic bacterium that is a poster child of deadly hospital acquired infections, is one tough customer.

22 Aug 2012

Wound dressing containing ionic silver capable of killing multidrug-resistant organisms

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced in vitro study results showing that a wound dressing containing ionic silver is able to kill several strains of multidrug-resistant organisms (MDROs), commonly referred to as 'superbugs.' The study results were published in the August issue of the International Wound Journal.

13 Aug 2012

Healthcare professionals receive SingHealth Duke-NUS Scientific Congress abstract awards

Results of the highly anticipated Best Oral Presentation and Best Poster Awards were announced at SingHealth Duke-NUS Scientific Congress 2012, held on 3 and 4 August 2012 at the Raffles City Convention Centre.

8 Aug 2012

Proper exsanguinator and tourniquet use poorly understood

Operating theater personnel have a poor understanding of appropriate exsanguinator and tourniquet use, show research results from a hospital in Ireland.

21 Jun 2012

MountainView Hospital first in Nevada to use Xenex’s room disinfection device

In an ongoing effort to improve patient safety, MountainView Hospital today announced it is the first hospital in Nevada to use Xenex Healthcare Services' innovative germ-zapping room disinfection technology to keep patients even safer from infections.

21 Jun 2012

BioMed Protect’s Sanotracin RTU rapidly and effectively kills C. difficile within 3 minutes

In the United States Clostridium difficile or "C. difficile" is now recognized as one of the most dangerous and fastest growing Healthcare Acquired Infections (HAIs) in existence. Now surpassing even Staphylococcus aureus (MRSA), C. difficile infections tripled between 2000 and 2005.

6 Jun 2012

New photoactive compound eradicates 'Iraqibacter' from wounds and skin infections

Researchers at the University of California, Santa Cruz, have developed a novel approach for eradicating drug-resistant bacteria from wounds and skin infections, using light to trigger the controlled release of nitric oxide. The UCSC team developed a photoactive compound that releases nitric oxide when exposed to light, and loaded it into a porous, biocompatible material that could be applied as a sprayable powder.

31 May 2012

Declining biodiversity may contribute to rise in asthma, allergies

Declining biodiversity may be contributing to the rise of asthma, allergies, and other chronic inflammatory diseases among people living in cities worldwide, a Finnish study suggests. Emerging evidence indicates that commensal microbes inhabiting the skin, airway, and gut protect against inflammatory disorders. However, little is known about the environmental determinants of the microbiome.

8 May 2012

Study identifies norovirus as major cause of all infection outbreaks in U.S. hospitals

Norovirus, a pathogen that often causes food poisoning and gastroenteritis, was responsible for 18.2 percent of all infection outbreaks and 65 percent of ward closures in U.S. hospitals during a two-year period, according to a new study published in the February issue of the American Journal of Infection Control (AJIC), the official publication of APIC - the Association for Professionals in Infection Control and Epidemiology.

1 Feb 2012